染色质互作揭示风湿病药物重定位的新基因靶点
本研究利用三种风湿病的Capture Hi-C数据,从B细胞和T细胞中鉴定高置信度候选因果基因,并结合DrugBank药物靶点信息及Ingenuity通路分析,筛选可重定位用于风湿病治疗的现有药物。共鉴定454个高置信度基因,其中48个为药物靶点(涉及108种药物),11个为已用于风湿病治疗的现有疗法;通路分析精炼后保留50个基因,13个为药物靶点(涉及33种药物),而考虑所有富集通路中的靶点则额外识别367种潜在可重定位药物。结论认为Capture Hi-C有望识别可重定位治疗风湿病的疗法,尤其在类风湿关节炎中成功识别六种有效生物制剂。
要点
- Capture Hi-C从B/T细胞鉴定454个高置信度候选因果基因,48个为药物靶点。
- 通路分析精炼后50个基因中13个为药物靶点,涉及33种药物。
- 考虑所有富集通路靶点额外识别367种潜在可重定位药物。
核心结论
- Capture Hi-C有潜力识别可重定位用于治疗风湿病的疗法,尤其在类风湿关节炎中成功识别六种有效生物制剂。
研究设计与样本
- 利用三种风湿病的Capture Hi-C数据从B细胞和T细胞中鉴定高置信度候选因果基因,并结合DrugBank药物靶点信息及Ingenuity通路分析筛选可重定位药物。
主要发现
- 共鉴定454个高置信度基因,其中48个为药物靶点(涉及108种药物),11个为已用于风湿病治疗的现有疗法。
- 通路分析精炼后保留50个基因,13个为药物靶点(涉及33种药物)。
- 考虑所有富集通路中的靶点,额外识别367种潜在可重定位药物。
临床怎么用
- 该策略可为风湿病(尤其类风湿关节炎)识别现有药物的新适应症,可能改善患者生活质量并减轻医疗经济负担。
局限性
- 随着更多细胞类型和其他表观基因组数据集产生,该前景将进一步提升。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is a need to identify effective treatments for rheumatic diseases, and while genetic studies have been successful it is unclear which genes contribute to the disease. Using our existing Capture Hi-C data on three rheumatic diseases, we can identify potential causal genes which are targets for existing drugs and could be repositioned for use in rheumatic diseases. METHODS: High confidence candidate causal genes were identified using Capture Hi-C data from B cells and T cells. These genes were used to interrogate drug target information from DrugBank to identify existing treatments, which could be repositioned to treat these diseases. The approach was refined using Ingenuity Pathway Analysis to identify enriched pathways and therefore further treatments relevant to the disease. RESULTS: Overall, 454 high confidence genes were identified. Of these, 48 were drug targets (108 drugs) and 11 were existing therapies used in the treatment of rheumatic diseases. After pathway analysis refinement, 50 genes remained, 13 of which were drug targets (33 drugs). However considering targets across all enriched pathways, a further 367 drugs were identified for potential repositioning. CONCLUSION: Capture Hi-C has the potential to identify therapies which could be repositioned to treat rheumatic diseases. This was particularly successful for rheumatoid arthritis, where six effective, biologic treatments were identified. This approach may therefore yield new ways to treat patients, enhancing their quality of life and reducing the economic impact on healthcare providers. As additional cell types and other epigenomic data sets are generated, this prospect will improve further.
引用
- Martin P, Ding J, Duffus K, et al. Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. Ann Rheum Dis. 2019. PMID: 31092410. doi:10.1136/annrheumdis-2018-214649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。